Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts

Transplantation

Volumn 66, Issue 12, 1998, Pages 1793-1801

  Djamali, Arjang ^a   Odorico, Jon S ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED MRL LPR; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032573687     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812270-00038     Document Type: Article

References (59)

1. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996; 14: 207.
2. Halloran PF, Broski AP, Batiuk TD, Madrenas J. The molecular immunology of acute rejection: an overview. Transpl Immunol 1993; 1: 3.
3. Deckers JG, Boonstra JG, Van der Kooij SW, Daha MR, van der Woude FJ. Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection. Transplantation 1997; 64: 178.
4. Christiaans MH, Overhof-de RR, Nieman F, van Hooff JP, van den Berg-Loonen EM. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65: 427.
5. Sirak J, Orosz CG, Wakely E, VanBuskirk AM. Alloreactive delayed-type hypersensitivity in graft recipients: complexity of responses and divergence from acute rejection. Transplantation 1997; 63: 1300.
6. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell 1997; 90: 13.
7. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31.
8. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994; 370: 650.
9. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449.
10. Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 1996; 157: 1919.
11. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994; 264: 667.
12. Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990.
13. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111.
14. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687.
15. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569.
16. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187: 587.
17. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355.
18. Kabelitz D, Pohl T, Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993; 14: 338.
19. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71.
20. Suda T, Nagata S. Why do defects in the Fas-Fas ligand system cause autoimmunity? J Allergy Clin Immunol 1997; 100: S97.
21. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990; 63: 1249.
22. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1: 365.
23. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
24. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
25. Biancone L, Martino AD, Orlandi V, Conaldi PG, Toniolo A, Camussi G. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 1997; 186: 147.
26. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429.
27. French LE, Tschopp J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt 1996; 97: 156.
28. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 1993; 90: 1756.
29. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969.
30. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39.
31. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243.
32. Benihoud K, Bonardelle D, Bobe P, Kiger N. MRL/lpr CD4-CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perform cytotoxic pathways. Eur J Immunol 1997; 27: 415.
33. Davidson WF, Dumont FJ, Bedigian HG, Fowlkes BJ, Morse HC. Phenotypic, functional, and molecular genetic comparisons of the abnormal lymphoid cells of C3H-lpr/lpr and C3H-gld/gld mice. J Immunol 1986; 136: 4075.
34. Davignon JL, Budd RC, Ceredig R, et al. Functional analysis of T cell subsets from mice bearing the lpr gene. J Immunol 1985; 135: 2423.
35. Igarashi S, Takiguchi M, Kariyone A, Kano K. Phenotypic and functional analyses on T-cell subsets in lymph nodes of MRL/ Mp-lpr/lpr mice. Int Arch Allergy Appl Immunol 1988; 86: 249.
36. Larsen CP, Alexander DZ, Hendrix R, Ritchie SC, Pearson TC. Fas-mediated cytotoxicity: an immunoeffector or immunoregulatory pathway in T cell-mediated immune responses? Transplantation 1995; 60: 221.
37. Yoshida R, Sanchez-Bueno A, Yamamoto N, Einaga-Naito K. Ca2+-dependent, Fas- and perforin-independent apoptotic death of allografted tumor cells by a type of activated macrophage. J Immunol 1997; 159: 15.
38. Ahmed KR, Guo TB, Gaal KK. Islet rejection in perforin-deficient mice: the role of perform and Fas. Transplantation 1997; 63: 951.
39. Seino K, Kayagaki N, Bashuda H, Okumura K, Yagita H. Contribution of Fas ligand to cardiac allograft rejection. Int Immunol 1996; 8: 1347.
40. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396.
41. George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein DR, Thomas JM. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med 1998; 4: 333.
42. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64: 1107.
43. Hodes R. Aging and the immune system. Immunol Rev 1997; 160: 5.
44. Fulmer R, Cramer A, Liebelt A. Transplantation of cardiac tissue into the mouse ear. Am J Anat 1963; 113: 273.
45. Judd K, Trentin J. Cardiac transplantation in mice. I. Factors influencing the take and survival of heterotopic grafts. Transplantation 1971; 11: 298.
46. Anonymous. Proliferative assays for T cell function. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current protocols in immunology. New York: John Wiley, 1991: 3.12.1
47. Davidson WF, Calkins C, Hugins A, Giese T, Holmes KL. Cytokine secretion by C3H-lpr and -gld T cells: Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+ T cells. J Immunol 1991; 146: 4138.
48. Laguens RP, Meckert PM, Martino JS, Perrone S, Favaloro R. Identification of programmed cell death (apoptosis) in situ by means of specific labeling of nuclear DNA fragments in heart biopsy samples during acute rejection episodes. J Heart Lung Transplant 1996; 15: 911.
49. Szaboles MJ, Ravalli S, Minanov O, Sciacca RR, Michler RE, Cannon PJ. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 1998; 65: 804.
50. Schulz M, Schuurman HJ, Joergensen J, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol 1995; 25(2): 474.
51. Selvaggi G, Ricordi C, Podack ER, Inverardi L. The role of the perform and Fas pathways of cytotoxicity in skin graft rejection. Transplantation 1996; 62: 1912.
52. Kabelitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 65: 869.
53. Ito H, Kasagi N, Shomori K, Osaki M, Adachi H. Apoptosis in the human allografted kidney: analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 1995; 60: 794.
54. Krams SM, Egawa H, Quinn MB, Villanueva JC, Garcia-Kennedy R, Martinez OM. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation 1995; 59: 621.
55. Sharma VK, Bologa RM, Li B, et al. Molecular executors of cell death: differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/ or chronic rejection of human renal allografts. Transplantation 1996; 62: 1860.
56. Qian S, Lu L, Fu F, et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol 1997; 158: 4654.
57. Swenson KM, Ke B, Wang T, et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998; 65: 155.
58. Lau HT, Yu M, Fontana A, Stoeckert CJJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
59. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317.